Experts say halting U.S. funds for Gavi vaccine alliance will cost lives
Johannesburg — Every four years, representatives to the global alliance of governments, pharmaceutical makers, United Nations agencies and philanthropic organizations known as Gavi, which helps get vaccines to people who need them, meet to lock in new funding pledges. Just as this year's meeting in Brussels was drawing to a close on Wednesday, U.S. Health Secretary Robert F. Kennedy Jr. announced that all funding from Washington would cease.
In a three-and-a-half-minute video message that Kennedy shared on social media, he said the Trump administration was halting funding to the organization because it had "neglected the key issue of vaccine safety."
Kennedy, who has sought to distance himself from the "anti-vaccine" label, has a history of making misleading statements about vaccine safety and has been tied to anti-vaccine activism groups.
Gavi says it has helped vaccinate more than 1.1 billion children in 78 low income countries and prevented more than 18.8 million deaths since its creation 25 years ago. Its focus is getting vaccines, especially new vaccines, to populations that would struggle to afford them or access them otherwise.
Kennedy argued in the video that GAVI "has neglected the key issue of vaccine safety," and that "when vaccine safety issues have come before Gavi, Gavi has treated them not as a patient health problem, but as a public relations problem."
Kennedy accused GAVI of ignoring the science and said the alliance must "justify the $8 billion the U.S. has given it since 2001."
The U.S. has long been among the top government contributors to Gavi's funding, which also comes from private organizations.
The Biden administration had committed to $1.6 billion in funding for the organization from 2026 through 2030 — an amount roughly equal to the funding pledged by the private Gates Foundation — and shock and outrage reverberated across the conference in Brussels after Kennedy's announcement.
Bill Gates, co-founder of Microsoft and the Gates Foundation, said on social media that the move would have "devastating consequences." He called on the U.S. Congress to keep funding Gavi, warning that if it did not, "more sick kids will fall behind in school," and there would be "more overcrowded hospital wards and eventually more grieving parents."
"If Congress allows this to happen, the consequences will be devastating," Gates Foundation CEO Mark Suzman said. "Hundreds of thousands, if not millions, of preventable deaths will occur, especially among mothers and children."
Dr. Atul Gawande, a public health researcher and surgeon at the Brigham and Women's Hospital in Boston who previously held a seat on the Gavi board, said Kennedy would be held personally responsible for the results of halted U.S. government funding, which he called a "travesty and a nightmare."
"I would expect to see significant changes and reductions in access to safe and effective vaccines to children, in the poorest and most vulnerable countries of the world," one U.S. official with decades of experience in global health and vaccination programs told CBS News on the condition of anonymity. "Kennedy's rhetoric on vaccine safety is not helpful and is likely to fuel vaccine hesitancy in the minds of people across the world, where we will surely now see more uncontrolled outbreaks of vaccine-preventable diseases. This is very unfortunate."
The U.N.'s World Health Organization has warned since 2019 that vaccine hesitancy and mistrust is one of the leading threats to global public health.
The goal of this year's conference was to secure funding to reach the organization's target of over 90% global coverage with essential vaccines for a wide range of diseases such as diphtheria, tetanus and measles. Gavi received more than $9 billion in funding commitments on Wednesday, but it had hoped to garner $11.9 billion for the next five years, with the goal of immunizing 500 million children globally.
Other countries acknowledged Gavi's importance, and increased their contributions at the conference on Wednesday.
Topping that list was the U.K.
British Foreign Secretary David Lammy announced $1.7 billion for the coming five years, making the U.K. Gavi's new largest donor.
Ghana's President John Darami Mahama, addressing the Gavi conference on Wednesday, began by detailing his younger brother's struggle with polio, and the stigma associated with the disease, which has been virtually eradicated worldwide thanks to vaccination programs launched in the late 1980s.
"I understand the importance of vaccines," Mahama told the delegations.
When his brother was diagnosed, vaccine access in Ghana was close to zero, but the president said that, through partnership with Gavi, 97% of the population was now vaccinated.
He said officials were still working to reach the last 3% — about "65,000 children who are in remote areas, difficult to reach for life saving vaccines" — and that Ghana planned to no longer need Gavi's support by 2030.
Mahama concluded his remarks with a topical comparison, saying: "One B-2 Spirit Bomber that dropped bombs on Iran cost $2.13 billion," and that he had done the math, adding: "Surely the world can afford the value of four B-2 bombers to save 500 million children. It's a choice we have to make."
Young Cuban girl asks Trump to lift travel ban stopping her from joining mom in U.S.
Images of newly-discovered exoplanet captured by James Webb Telescope
RFK Jr.'s CDC vaccine panel recommends against flu vaccines containing thimerosal
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
HCA Healthcare Foundation Awards $1 Million Grant to Educate Texas for Healthcare Career Pathways
HCA Healthcare Inc. (NYSE:HCA) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 26, HCA Healthcare announced that its HCA Healthcare Foundation, through its Healthier Tomorrow Fund, will provide a new $1 million grant to Educate Texas, which is an initiative of Communities Foundation of Texas. HCA Healthcare Foundation promotes health and well-being across all the communities HCA Healthcare serves The latest donation expands upon a previous $1.35 million grant made by the Foundation to Educate Texas in 2022. The funding aims to increase student access to programs that prepare them for careers in healthcare, specifically focusing on high schools in Texas that offer Pathways in Technology Early College High School (P-TECH) healthcare career tracks. The initial 2022 grant supported the expansion of healthcare career pathways across P-TECH campuses, growing from 20 to 104 schools and enrolling ~10,000 high school students in these specialized programs. A team of healthcare professionals in lab coats and masks meeting at a hospital ward. The new $1 million grant will enable Educate Texas to further enhance the quality of program implementation. The initiative seeks to increase the number of students earning healthcare degrees and credentials and foster greater engagement of hospital employers, including HCA Healthcare-affiliated hospitals, with school districts in North Texas, Austin, San Antonio, and the Houston Gulf Coast region. HCA Healthcare Inc. (NYSE:HCA) owns and operates hospitals and related healthcare entities in the US. While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, BioMarin Pharmaceutical Inc. presented new 5-year data from its Phase 3 GENEr8-1 trial at the 33rd Congress of the International Society on Thrombosis and Haemostasis/ISTH in Washington, D.C., which took place from June 21 to 25. The data reinforced the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) as a gene therapy for severe hemophilia A. The GENEr8-1 trial is the longest and largest hemophilia gene therapy study to date, and demonstrated sustained Factor VIII (FVIII) expression and durable bleed control 5 years after a single treatment with ROCTAVIAN. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. FVIII activity remained consistent with previously reported results. Importantly, no new safety signals were observed over the 5-year study period. Across all 134 participants who received ROCTAVIAN in the study, there were no cases of FVIII inhibitors or thromboembolic events, and no treatment-related malignancies were observed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions internationally. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio